Display options
Cite
Beier EE, Sheu TJ, Resseguie EA, et al. Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice. Bone Res. 2017;5:17013doi: 10.1038/boneres.2017.13.
Beier, E. E., Sheu, T. J., Resseguie, E. A., Takahata, M., Awad, H. A., Cory-Slechta, D. A., & Puzas, J. E. (2017). Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice. Bone research, 517013. https://doi.org/10.1038/boneres.2017.13
Beier, Eric E, et al. "Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice." Bone research vol. 5 (2017): 17013. doi: https://doi.org/10.1038/boneres.2017.13
Beier EE, Sheu TJ, Resseguie EA, Takahata M, Awad HA, Cory-Slechta DA, Puzas JE. Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice. Bone Res. 2017 May 09;5:17013. doi: 10.1038/boneres.2017.13. eCollection 2017. PMID: 28529816; PMCID: PMC5422922.
Copy Download .nbib Format: NLM
Share it on

Bone Res. 2017 May 09;5:17013. doi: 10.1038/boneres.2017.13. eCollection 2017.

Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice.

Bone research

Eric E Beier, Tzong-Jen Sheu, Emily A Resseguie, Masahiko Takahata, Hani A Awad, Deborah A Cory-Slechta, J Edward Puzas

Affiliations

  1. Department of Environmental Medicine, University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA.
  2. Department of Environmental and Occupational Medicine, Rutgers University, Piscataway, NJ, USA.
  3. Center for Musculoskeletal Research, University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA.

PMID: 28529816 PMCID: PMC5422922 DOI: 10.1038/boneres.2017.13

Abstract

Stress during prenatal development is correlated with detrimental cognitive and behavioral outcomes in offspring. However, the long-term impact of prenatal stress (PS) and disrupted glucocorticoid signaling on bone mass and strength is not understood. In contrast, the detrimental effect of lead (Pb) on skeletal health is well documented. As stress and Pb act on common biological targets via glucocorticoid signaling pathways and co-occur in the environment, this study first sought to assess the combined effect of stress and Pb on bone quality in association with alterations in glucocorticoid signaling. Bone parameters were evaluated using microCT, histomorphometry, and strength determination in 8-month-old male mouse offspring subjected to PS on gestational days 16 and 17, lifetime Pb exposure (100 p.p.m. Pb in drinking water), or to both. Pb reduced trabecular bone mass and, when combined with PS, Pb unmasked an exaggerated decrement in bone mass and tensile strength. Next, to characterize a mechanism of glucocorticoid effect on bone, prednisolone was implanted subcutaneously (controlled-release pellet, 5 mg·kg

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Clin Calcium. 2006 Nov;16(11):1812-6 - PubMed
  2. Osteoporos Int. 2013 Aug;24(8):2191-9 - PubMed
  3. J Bone Miner Res. 2000 Jan;15(1):2-12 - PubMed
  4. Dev Psychopathol. 2001 Summer;13(3):653-76 - PubMed
  5. Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1526-33 - PubMed
  6. Neurotoxicology. 2008 Nov;29(6):928-39 - PubMed
  7. J Bone Miner Res. 2008 Jun;23 (6):860-9 - PubMed
  8. BMC Musculoskelet Disord. 2010 Sep 15;11:210 - PubMed
  9. Toxicol Appl Pharmacol. 2009 Jan 1;234(1):117-27 - PubMed
  10. Metabolism. 2008 Oct;57 Suppl 2:S11-5 - PubMed
  11. Toxicol Sci. 2010 Oct;117(2):427-38 - PubMed
  12. Calcif Tissue Int. 2013 Aug;93(2):121-32 - PubMed
  13. Cell. 2002 Nov 1;111(3):305-17 - PubMed
  14. J Clin Endocrinol Metab. 2010 Nov;95(11):4795-801 - PubMed
  15. J Biol Chem. 2015 Jul 17;290(29):18216-26 - PubMed
  16. Arthritis Rheum. 2012 Nov;64(11):3649-59 - PubMed
  17. Bone. 2002 May;30(5):685-91 - PubMed
  18. Arthritis Rheum. 2008 Jun;58(6):1674-86 - PubMed
  19. Mol Cell Neurosci. 1994 Oct;5(5):385-93 - PubMed
  20. Biochem J. 2003 Dec 15;376(Pt 3):607-13 - PubMed
  21. J Bone Miner Res. 2012 Nov;27(11):2242-50 - PubMed
  22. Front Biosci. 2008 Jan 01;13:898-903 - PubMed
  23. J Endocrinol. 2002 Sep;174(3):411-8 - PubMed
  24. Environ Toxicol. 2017 Apr;32(4):1333-1342 - PubMed
  25. J Invest Dermatol. 1997 Jun;108(6):938-42 - PubMed
  26. Endocrinology. 2008 Apr;149(4):1793-801 - PubMed
  27. PLoS One. 2010 Jul 30;5(7):e11896 - PubMed
  28. Burns. 2015 Nov;41(7):1532-5 - PubMed
  29. Biomaterials. 2004 Feb;25(5):757-68 - PubMed
  30. J Bone Miner Res. 2006 Mar;21(3):466-76 - PubMed
  31. J Endocrinol. 2005 Sep;186(3):R7-R12 - PubMed
  32. Neurotoxicology. 2011 Jan;32(1):83-99 - PubMed
  33. Paediatr Perinat Epidemiol. 2008 Sep;22(5):438-66 - PubMed
  34. J Bone Miner Res. 2007 Oct;22(10 ):1571-80 - PubMed
  35. Environ Health Perspect. 2004 May;112(6):717-30 - PubMed
  36. Cell. 2000 Jan 21;100(2):197-207 - PubMed
  37. J Cell Biochem. 2000 Jan;76(3):518-27 - PubMed
  38. Ann N Y Acad Sci. 1999;896:30-47 - PubMed
  39. Arthritis Rheum. 2008 Nov;58(11):3485-97 - PubMed
  40. Am J Epidemiol. 2004 Nov 1;160(9):901-11 - PubMed
  41. Environ Health Perspect. 2013 Jan;121(1):97-104 - PubMed
  42. Bone. 2013 Nov;57(1):272-6 - PubMed
  43. J Biol Chem. 2000 Jun 30;275(26):19992-20001 - PubMed
  44. Miner Electrolyte Metab. 1997;23(2):65-73 - PubMed
  45. Clin Chim Acta. 2003 Jul 1;333(1):1-11 - PubMed
  46. Ann N Y Acad Sci. 2002 Jun;966:73-81 - PubMed
  47. Bone. 2007 Jan;40(1):84-92 - PubMed
  48. Ann N Y Acad Sci. 2002 Jun;967:379-88 - PubMed
  49. Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S77-9 - PubMed
  50. J Bone Miner Res. 2013 Jan;28(1):2-17 - PubMed
  51. Clin Rheumatol. 2007 Feb;26(2):144-53 - PubMed
  52. J Orthop Res. 2014 Nov;32(11):1397-405 - PubMed
  53. Osteoporos Int. 2007 Oct;18(10):1319-28 - PubMed
  54. Am J Stem Cells. 2012 Nov 30;1(3):205-24 - PubMed
  55. Arch Womens Ment Health. 2010 Feb;13(1):83-9 - PubMed
  56. Semin Reprod Med. 2008 Sep;26(5):436-45 - PubMed
  57. Endocrinology. 1997 May;138(5):2117-27 - PubMed
  58. Toxicol Sci. 2005 Oct;87(2):469-82 - PubMed
  59. Neurosci Lett. 1997 May 16;227(2):119-22 - PubMed
  60. J Bone Miner Res. 2010 Oct;25(10):2115-25 - PubMed
  61. Nat Rev Rheumatol. 2009 Aug;5(8):442-7 - PubMed
  62. J Clin Endocrinol Metab. 2012 Oct;97(10):E1953-7 - PubMed
  63. Curr Pharm Des. 2010;16(32):3586-92 - PubMed
  64. Science. 2000 Aug 11;289(5481):950-3 - PubMed
  65. Biochem Biophys Res Commun. 2005 Apr 1;329(1):177-81 - PubMed
  66. Expert Opin Ther Targets. 2009 Apr;13(4):485-96 - PubMed
  67. Toxicol Sci. 2013 Jan;131(1):194-205 - PubMed
  68. Basic Clin Pharmacol Toxicol. 2008 Feb;102(2):218-27 - PubMed
  69. Eur J Endocrinol. 1997 Sep;137(3):209-17 - PubMed
  70. Endocrinology. 1984 May;114(5):1635-44 - PubMed
  71. Acad Pediatr. 2009 May-Jun;9(3):150-6 - PubMed
  72. Wiley Interdiscip Rev Dev Biol. 2014 Nov-Dec;3(6):489-500 - PubMed
  73. J Bone Miner Res. 2009 Oct;24(10):1651-61 - PubMed
  74. Environ Health Perspect. 2005 Jun;113(6):749-55 - PubMed
  75. Calcif Tissue Int. 2013 Apr;92(4):354-61 - PubMed
  76. Neurotoxicology. 2008 Sep;29(5):812-27 - PubMed
  77. Environ Health Perspect. 2015 Oct;123(10):935-43 - PubMed
  78. Early Hum Dev. 2011 Dec;87(12):813-20 - PubMed
  79. Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6545-9 - PubMed
  80. Pediatr Res. 2012 Jan;71(1):126-31 - PubMed

Publication Types